TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07908446: Phase 4, Randomized, Open-label, Non-inferiority Trial of Bictegravir/Lenacapavir Fixed-dose Combination (BIC/LEN FDC) Versus Stable Baseline Regimens (SBR) in Virologically Suppressed (VS) People With HIV (PWH)

Sponsor: Gilead Sciences · Phase: PHASE4 · Area: INFECTIOUS_VACCINE · Target Enrollment: 400 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,526,400

Rescue Site Savings

+$4,962,720

Unlock Full NCT07908446 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07908446 Rescue Dossier →